## Aruna D Pradhan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9250653/publications.pdf

Version: 2024-02-01

29 papers

3,027 citations

430874 18 h-index 25 g-index

29 all docs 29 docs citations

29 times ranked 5589 citing authors

#	Article	IF	CITATIONS
1	Time to commence or time out for colchicine in secondary prevention of cardiovascular disease?. European Heart Journal, 2021, 42, 2776-2779.	2.2	4
2	Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease. Circulation, 2021, 144, 353-364.	1.6	47
3	Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease. Clinical Chemistry, 2021, 67, 183-196.	3.2	58
4	Abstract 11848: Biomarkers of Glucose-Insulin Homeostasis, Randomized Treatment With Omega-3 and Vitamin D Supplementation, and Incident Type 2 Diabetes: Prospective Analysis From the Vitamin D and Omega-3 Trial (VITAL). Circulation, 2021, 144, .	1.6	0
5	Abstract 12860: Effects of Marine Omega-3 and Vitamin D Supplementation on Circulating Biomarkers of Glucose-Insulin Homeostasis and Incident Cardiovascular Disease in the Vitamin D and Omega-3 Trial (VITAL). Circulation, 2021, 144, .	1.6	0
6	Adverse Effects of Low-Dose Methotrexate. Annals of Internal Medicine, 2020, 172, 369.	3.9	126
7	Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease. Journal of the American College of Cardiology, 2020, 75, 2122-2135.	2.8	160
8	The Big MAC Attack on Peripheral Artery Disease. Circulation, 2020, 141, 1211-1213.	1.6	7
9	Association of the Mediterranean Diet With Onset of Diabetes in the Women's Health Study. JAMA Network Open, 2020, 3, e2025466.	5.9	28
_			
10	A New Beginning for Triglyceride-Lowering Therapies. Circulation, 2019, 140, 167-169.	1.6	6
10	A New Beginning for Triglyceride-Lowering Therapies. Circulation, 2019, 140, 167-169.  Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology. American Journal of Human Genetics, 2019, 105, 15-28.	1.6 6.2	21
	Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology. American Journal		
11	Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology. American Journal of Human Genetics, 2019, 105, 15-28.  Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of	6.2	21
11 12	Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology. American Journal of Human Genetics, 2019, 105, 15-28.  Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine, 2019, 380, 752-762.  Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy. Circulation, 2018,	6.2 27.0	21 886
11 12 13	Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology. American Journal of Human Genetics, 2019, 105, 15-28.  Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine, 2019, 380, 752-762.  Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy. Circulation, 2018, 138, 141-149.  Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal	6.2 27.0 1.6	21 886 151
11 12 13	Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology. American Journal of Human Genetics, 2019, 105, 15-28.  Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine, 2019, 380, 752-762.  Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy. Circulation, 2018, 138, 141-149.  Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the American College of Cardiology, 2018, 71, 2392-2401.  Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing	6.2 27.0 1.6 2.8	21 886 151 236
11 12 13 14	Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology. American Journal of Human Genetics, 2019, 105, 15-28.  Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine, 2019, 380, 752-762.  Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy. Circulation, 2018, 138, 141-149.  Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the American College of Cardiology, 2018, 71, 2392-2401.  Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.  Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence. Circulation,	6.2 27.0 1.6 2.8	21 886 151 236 276

#	Article	IF	CITATIONS
19	Hemoglobin A1c levels and risk of sudden cardiac death: A nested case-control study. Heart Rhythm, 2017, 14, 72-78.	0.7	14
20	Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. Nature Communications, 2016, 7, 10494.	12.8	153
21	Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations. American Journal of Cardiology, 2016, 117, 376-381.	1.6	10
22	Update on the Vitamin D and OmegA-3 trial (VITAL). Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 252-256.	2.5	69
23	Novel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1544-1550.	2.4	105
24	Abstract 19720: Jay D. Coffman Early Career Investigator Award: Comparative Efficacy of Initial Endovascular Revascularization vs. Supervised Exercise Training in Patients With Intermittent Claudication: A Meta-analysis of Randomized Controlled Trials. Circulation, 2015, 132, .	1.6	0
25	Sex Differences in the Metabolic Syndrome: Implications for Cardiovascular Health in Women. Clinical Chemistry, 2014, 60, 44-52.	3.2	202
26	Response to Letter Regarding Article, "Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Eventsâ€. Circulation, 2007, 115, .	1.6	0
27	Obesity, Metabolic Syndrome, and Type 2 Diabetes: Inflammatory Basis of Glucose Metabolic Disorders. Nutrition Reviews, 2007, 65, S152-S156.	5.8	90
28	C-Reactive Protein Is Independently Associated With Fasting Insulin in Nondiabetic Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 650-655.	2.4	182
29	Plasma Concentration of Interleukin-6 and C-reactive Protein and the Risk of Developing Type 2 Diabetes Mellitus Among Healthy Middle-Aged Women. Circulation, 2001, 103, 1351-1351.	1.6	2